INT4397

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1975
Last Reported 2007
Negated 0
Speculated 1
Reported most in Abstract
Documents 7
Total Number 8
Disease Relevance 0.65
Pain Relevance 0.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CSH1) extracellular region (CSH1)
CSH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Enkephalin 5 87.24 High High
Bioavailability 90 80.72 Quite High
psoriasis 2 61.12 Quite High
Arthritis 2 60.28 Quite High
ischemia 1 58.04 Quite High
Dismenorea 1 57.40 Quite High
Bile 4 5.00 Very Low Very Low Very Low
Analgesic 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Taxol 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Intrahepatic Cholestasis 1 87.20 High High
Rupture 2 77.20 Quite High
Pre-eclampsia 1 61.36 Quite High
Psoriasis 2 61.12 Quite High
Arthritis 2 60.28 Quite High
Graft Vs Host Disease 2 58.24 Quite High
Cv Unclassified Under Development 1 58.04 Quite High
Dysmenorrhea 1 57.40 Quite High
Organ Transplantation 2 56.72 Quite High
Toxicity 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Specific expression of testicular GH/PL mRNA (n = 20) was shown by reverse transcription-polymerase chain reaction (RT-PCR) using a pair of primers designed to non-selectively amplify any transcript of the five GH/PL genes (GH-N, GH-V, PL-A, PL-B, PL-L).
Transcription (transcript) of PL
1) Confidence 0.57 Published 1997 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 9220021 Disease Relevance 0 Pain Relevance 0.08
Specific expression of testicular GH/PL mRNA (n = 20) was shown by reverse transcription-polymerase chain reaction (RT-PCR) using a pair of primers designed to non-selectively amplify any transcript of the five GH/PL genes (GH-N, GH-V, PL-A, PL-B, PL-L).
Transcription (transcript) of PL-L
2) Confidence 0.57 Published 1997 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 9220021 Disease Relevance 0 Pain Relevance 0.08
Specific expression of testicular GH/PL mRNA (n = 20) was shown by reverse transcription-polymerase chain reaction (RT-PCR) using a pair of primers designed to non-selectively amplify any transcript of the five GH/PL genes (GH-N, GH-V, PL-A, PL-B, PL-L).
Transcription (transcript) of PL
3) Confidence 0.55 Published 1997 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 9220021 Disease Relevance 0 Pain Relevance 0.08
Specific expression of testicular GH/PL mRNA (n = 20) was shown by reverse transcription-polymerase chain reaction (RT-PCR) using a pair of primers designed to non-selectively amplify any transcript of the five GH/PL genes (GH-N, GH-V, PL-A, PL-B, PL-L).
Transcription (transcript) of PL-B
4) Confidence 0.55 Published 1997 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 9220021 Disease Relevance 0 Pain Relevance 0.08
Specific expression of testicular GH/PL mRNA (n = 20) was shown by reverse transcription-polymerase chain reaction (RT-PCR) using a pair of primers designed to non-selectively amplify any transcript of the five GH/PL genes (GH-N, GH-V, PL-A, PL-B, PL-L).
Transcription (expression) of PL
5) Confidence 0.48 Published 1997 Journal Mol. Cell. Endocrinol. Section Abstract Doc Link 9220021 Disease Relevance 0 Pain Relevance 0.09
Human placental lactogen levels during and after labor.
Transcription (levels) of placental lactogen
6) Confidence 0.43 Published 1975 Journal Obstet Gynecol Section Title Doc Link 1153151 Disease Relevance 0.41 Pain Relevance 0.09
Drewe and colleagues investigated the absorption of CsA (150 mg) from three experimental formulations using Sandimmune as reference in fasting healthy volunteers.
Spec (investigated) Transcription (absorption) of CsA
7) Confidence 0.17 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2374933 Disease Relevance 0.24 Pain Relevance 0.06
This could suggest that the absorption of CsA from the Sandimmune formulation was limited by gastric emptying or the food consumed 4 h after administration.
Transcription (absorption) of CsA
8) Confidence 0.17 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2374933 Disease Relevance 0 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox